CR9443A - Vacuna de toxoide de c. perfringens alfa - Google Patents

Vacuna de toxoide de c. perfringens alfa

Info

Publication number
CR9443A
CR9443A CR9443A CR9443A CR9443A CR 9443 A CR9443 A CR 9443A CR 9443 A CR9443 A CR 9443A CR 9443 A CR9443 A CR 9443A CR 9443 A CR9443 A CR 9443A
Authority
CR
Costa Rica
Prior art keywords
perfringens
alfa
vaccines
toxoid vaccine
present
Prior art date
Application number
CR9443A
Other languages
English (en)
Inventor
Jayappa Huchappa
O'connell Kevin
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36820082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9443(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of CR9443A publication Critical patent/CR9443A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion describe vacunas que comprenden toxoides alfa de un Tipo C. perfringens, sus fragmentos antigenicos, fragmentos antigenicos inactivos de toxinas alfa de un Tipo C. perfrigens, o cualquiera de sus combinaciones. La presente invencion ademas describe metodos para el uso de estas vacunas en la proteccion de animales contra enfermedades clostridiales. La presente invencion describe tambien metodos para la elaboracion de estas vacunas.
CR9443A 2005-04-18 2007-10-16 Vacuna de toxoide de c. perfringens alfa CR9443A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67228905P 2005-04-18 2005-04-18

Publications (1)

Publication Number Publication Date
CR9443A true CR9443A (es) 2008-02-20

Family

ID=36820082

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9443A CR9443A (es) 2005-04-18 2007-10-16 Vacuna de toxoide de c. perfringens alfa

Country Status (25)

Country Link
US (2) US8980283B2 (es)
EP (1) EP1874344B1 (es)
JP (2) JP5243951B2 (es)
KR (1) KR20080005277A (es)
CN (1) CN101198352B (es)
AR (1) AR054251A1 (es)
AU (1) AU2006236365B2 (es)
BR (1) BRPI0610843B1 (es)
CA (1) CA2606180C (es)
CR (1) CR9443A (es)
DK (1) DK1874344T3 (es)
ES (1) ES2583484T3 (es)
IL (1) IL186701A0 (es)
MA (1) MA29406B1 (es)
MX (1) MX2007013053A (es)
MY (1) MY149604A (es)
NZ (1) NZ562637A (es)
PE (1) PE20061398A1 (es)
RU (1) RU2434638C2 (es)
SG (1) SG186672A1 (es)
TN (1) TNSN07387A1 (es)
TW (1) TWI311057B (es)
UA (1) UA98099C2 (es)
WO (1) WO2006113772A1 (es)
ZA (1) ZA200709516B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149604A (en) * 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
RU2409385C2 (ru) * 2006-03-30 2011-01-20 Эмбрекс, Инк. Способ иммунизации птицы против инфекции, вызванной бактериями clostridium
US7732187B2 (en) 2006-04-17 2010-06-08 Intervet Inc. Recombinant attenuated clostridium organisms and vaccine
CN101578109A (zh) 2006-10-27 2009-11-11 陶氏益农公司 用于坏死性肠炎的、包含突变的产气荚膜梭菌α毒素抗原的家禽疫苗及生产疫苗的方法
KR20090081389A (ko) * 2006-11-20 2009-07-28 인터벳 인터내셔널 비.브이. 백신의 제조를 위한 클로스트리디움 퍼프린젠스 ｃ 형 박테리아의 용도
CA2629790C (en) * 2007-04-12 2015-06-30 Nutratech Use of avian anti-methanogen antibodies for reduction of methane production
WO2009000066A1 (en) * 2007-06-22 2008-12-31 University Of Guelph Vaccine against clostridium perfringens
WO2009076668A2 (en) * 2007-12-13 2009-06-18 Alpharma, Inc. Bacteriophage preparations and method of use thereof
US8277650B2 (en) 2009-03-13 2012-10-02 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
WO2011103465A2 (en) * 2010-02-20 2011-08-25 Alexey Gennadievich Zdanovsky Botulinum neurotoxin antigenic compositions and methods
WO2011151941A1 (ja) * 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
CN102008720B (zh) * 2010-07-20 2015-02-25 东北农业大学 抗魏氏梭菌病转基因植物疫苗及其制作方法
WO2013091895A1 (en) * 2011-12-23 2013-06-27 Merz Pharma Gmbh & Co. Kgaa Novel method for the manufacturing of di-chain proteins for use in humans
CN102657683B (zh) * 2012-06-02 2014-05-07 哈尔滨工业大学 一种免疫类毒素的制备方法
CN102698259B (zh) * 2012-06-12 2017-02-08 北京中海生物科技有限公司 一种鸡坏死性肠炎（a型）灭活疫苗制备方法
CN102688484B (zh) * 2012-06-13 2016-03-30 北京中海生物科技有限公司 一种鸡坏死性肠炎（c型）灭活疫苗的生产方法
MX364733B (es) 2012-10-26 2019-05-06 Intervet Int Bv Vacunas de salmonella de protección cruzada.
CN103463632B (zh) * 2013-09-05 2016-01-06 山东农业大学 牛羊肠毒血症的d型产气荚膜梭菌类毒素疫苗的制备方法
FR3012964A1 (fr) * 2013-11-12 2015-05-15 Seppic Sa Vaccins adjuves pour vaccination aviaire in ovo
CN103861094A (zh) * 2014-03-27 2014-06-18 山东农业大学 一种产气荚膜梭菌α毒素基因工程疫苗及其应用
CN104131022A (zh) * 2014-08-01 2014-11-05 中国农业科学院兰州兽医研究所 产气荚膜梭菌α、β1、β2、ε毒素共表达载体及其构建方法和表达方法
CN104531731B (zh) * 2014-12-15 2018-06-26 中国人民解放军军事医学科学院军事兽医研究所 产气荚膜梭菌α毒素人源化单链抗体7D
CN104531730B (zh) * 2014-12-15 2018-07-17 中国人民解放军军事医学科学院军事兽医研究所 产气荚膜梭菌α毒素人源化单链抗体8B
CN104531867B (zh) * 2014-12-25 2017-03-29 湖北省农业科学院畜牧兽医研究所 产气荚膜梭菌肠毒素阳性菌双重荧光定量pcr快速检测试剂盒
EP3112474A1 (en) * 2015-06-29 2017-01-04 Evonik Degussa GmbH Method of detecting avian necrotic enteritis
US10988729B2 (en) 2017-01-23 2021-04-27 University Of Florida Research Foundation, Incorporated Induction of protective immunity against antigens
WO2018159476A1 (ja) * 2017-02-28 2018-09-07 一般財団法人阪大微生物病研究会 多価ワクチン
BR112019025019A2 (pt) * 2017-05-31 2020-06-30 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food polipeptídeo isolado de pilus de clostridium perfringens, polipeptídeo imunogênico, vetor, vacina, uso de um polipeptídeo imunogênico, método de tratamento, anticorpo, método para detectar infecção e método para detectar um polipeptídeo imunogênico
JP7349366B2 (ja) * 2017-06-09 2023-09-22 ヒプラ シエンティフィック エセ．エレ．ウ． クロストリジウム類毒素を含むワクチン
CN111182920B (zh) 2017-08-04 2023-09-12 佛罗里达大学研究基金公司 针对抗原的保护性免疫的诱导
CN107596361B (zh) * 2017-09-12 2020-08-14 浙江海隆生物科技有限公司 牛a型产气荚膜梭菌的亚单位疫苗及其制备方法和应用
CN107875377B (zh) * 2017-11-06 2020-01-03 山东农业大学 一种e型产气荚膜梭菌类毒素疫苗的制备方法
CN109954135B (zh) * 2017-12-25 2023-01-31 金宇保灵生物药品有限公司 牛a型产气荚膜梭菌灭活类毒素疫苗及其制备方法
CN108578686B (zh) * 2018-04-23 2022-07-01 杨凌凯瑞生物科技有限公司 一种制备羊梭菌病基因工程亚单位疫苗的方法
CN109111509B (zh) * 2018-09-19 2021-08-13 天康制药(苏州)有限公司 腐败梭菌α毒素突变体、表达其的基因、制备方法和腐败梭菌疫苗
CN111500482B (zh) * 2019-01-31 2023-09-05 内蒙古金宇保灵生物技术研究院有限公司 一种羊a型产气荚膜梭菌菌株及其灭活疫苗和疫苗制备方法
CN109943507B (zh) * 2019-03-26 2021-08-17 中国兽医药品监察所 一种兽用a型产气荚膜梭菌类毒素的制备方法及其应用
CN110041437B (zh) * 2019-04-29 2020-12-25 中国兽医药品监察所 一种无毒性破伤风毒素和诺维梭菌α毒素重组融合蛋白

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2257230B1 (es) 1973-09-14 1976-11-19 Agronomique Inst Nat Rech
SU627612A1 (ru) * 1977-09-30 1980-02-05 Zemlyakova V P Препарат земл ковой в.п. против клюстридиозов животных и птиц
CA2136230C (en) 1992-05-20 2008-11-18 Richard W. Titball Clostridium perfringens vaccines
WO1994022476A1 (en) * 1993-03-29 1994-10-13 Pfizer Inc. Multicomponent clostridial vaccines using saponin adjuvants
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
CA2486618C (en) 2002-05-21 2013-04-09 Schering-Plough Ltd. Methods for the in vitro culture of sporozoea sp. and uses thereof
ATE505538T1 (de) * 2003-06-09 2011-04-15 Corixa Corp Dna-vektoren
JP2007502292A (ja) * 2003-08-14 2007-02-08 メリアル リミテッド クリプトスポリジウム・パルブムの抗原と他の病原体の抗原とを含む組成物及びワクチン
CA2897112A1 (en) * 2004-10-05 2006-04-20 Fvg Limited Compositions comprising an antigen and a promiscuous t-cell epitope
MY149604A (en) * 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
KR20090081389A (ko) 2006-11-20 2009-07-28 인터벳 인터내셔널 비.브이. 백신의 제조를 위한 클로스트리디움 퍼프린젠스 ｃ 형 박테리아의 용도

Also Published As

Publication number Publication date
AU2006236365A1 (en) 2006-10-26
EP1874344A1 (en) 2008-01-09
NZ562637A (en) 2010-06-25
US20060233825A1 (en) 2006-10-19
UA98099C2 (uk) 2012-04-25
EP1874344B1 (en) 2016-06-08
ES2583484T3 (es) 2016-09-21
RU2007142337A (ru) 2009-05-27
MA29406B1 (fr) 2008-04-01
RU2434638C2 (ru) 2011-11-27
JP2012062330A (ja) 2012-03-29
CN101198352A (zh) 2008-06-11
MX2007013053A (es) 2008-01-14
JP5243951B2 (ja) 2013-07-24
US8980283B2 (en) 2015-03-17
CA2606180A1 (en) 2006-10-26
AR054251A1 (es) 2007-06-13
SG186672A1 (en) 2013-01-30
AU2006236365B2 (en) 2012-02-02
DK1874344T3 (en) 2016-09-19
TW200719910A (en) 2007-06-01
CA2606180C (en) 2016-09-13
MY149604A (en) 2013-09-13
US20150140033A1 (en) 2015-05-21
CN101198352B (zh) 2011-07-27
US9662380B2 (en) 2017-05-30
ZA200709516B (en) 2008-11-26
JP2008536936A (ja) 2008-09-11
TWI311057B (en) 2009-06-21
IL186701A0 (en) 2008-02-09
PE20061398A1 (es) 2007-01-15
BRPI0610843B1 (pt) 2021-11-30
TNSN07387A1 (en) 2009-03-17
BRPI0610843A2 (pt) 2010-07-27
WO2006113772A1 (en) 2006-10-26
KR20080005277A (ko) 2008-01-10

Similar Documents

Publication Publication Date Title
CR9443A (es) Vacuna de toxoide de c. perfringens alfa
CL2019003636A1 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson.
ECSP099079A (es) Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos
CR11122A (es) Vacuna de influenza de emulsion de aceite en agua
BRPI0510430A (pt) composições e métodos para vacinação mucosal
BRPI0509606A (pt) emulsões de óleo-em-água microfluidizadas e composições para vacinas
BRPI0509528A (pt) corpos imitação de glp-1 humana, composições, processos e usos
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CR10726A (es) Vacuna que comprende un adyuvante de emulsion de aceite en agua
CO6331297A2 (es) Composiciones adyuvantes novedosas
RS52188B (en) A PSYCHI VACCINE FOR THE PROTECTION OF ERLIHIOSIS
CR9606A (es) Anticuerpos anti-proteina quinoatrayente de monocitos-1, composiciones, metodos y usos
CO6270335A2 (es) Anticuerpos anti-amiloide humanos composiciones metodos y usos
UY30820A1 (es) Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
AR060565A1 (es) Vacuna para la gripe aviaria y metodos de uso
WO2007024947A3 (en) Canine influenza vaccines
NI201100025A (es) Métodos de administración de las formulaciones tópicas antimicóticas para el tratamiento de las infecciones por hongos.
GT201100145A (es) Vacuna recombinante para influenza aviar y sus usos
GT200500094A (es) Formulaciones liquidas administrables pro via dermica para combatir artropodos parasitos en animales
PH12015501875A1 (en) Acellular pertussis vaccine
BR112019004303A2 (pt) composição de conjugados multivalentes de polissacarídeo capsular pneumocócico-proteína portadora e uso da mesma
SV2006002290A (es) Nonadepsipeptidos acilados ii ref. bhc041327-sv
MX2016001695A (es) Composiciones inmunogenas de combinacion.
BR112014020025A8 (pt) Vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
GB2444676A (en) Adjuvanted vaccine